secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001558370-24-014334
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure Q3 net loss $44.4M; cash runway through 2027; FDA meeting for Huntington gene therapy
--------------------------------------------------------------------------------

- Net loss $44.4M ($0.91/share) vs $89.6M ($1.88) in Q3 2023; revenue $2.3M (up from $1.4M).
- Cash $435.2M as of Sep 30; retired $50M debt; expects cash runway through end of 2027.
- Sold Lexington facility and restructured, cutting ~65% of roles (300) and reducing cash burn by $70M/year.
- Type B FDA meeting scheduled late Nov 2024 to discuss accelerated pathway for AMT-130 in Huntington's disease.
- Positive interim data at 24 months: AMT-130 high dose showed significant slowing of disease progression (p=0.007) and NfL reduction (p=0.02).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000155837024014334/0001558370-24-014334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000155837024014334/qure-20241105x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-014334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer